Compare Ascendis Pharma A/S (ASND) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Koninklijke Philips NV — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Koninklijke Philips NV trades at $27.4 (market cap $26.63B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays a 3.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PHG | |
|---|---|---|
Market Cap | $17.74B | $26.63B |
Sector | Health | Health |
52-Week High | $277.18 | $32.91 |
52-Week Low | $163.32 | $24.03 |
Enterprise Value | $18.11B | $32.90B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Royal Philips (PHG) trades at $27.40, up 0.51% today, with a bullish technical signal despite mixed moving averages. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight growth initiatives. Analyst consensus leans neutral with 40.9% buy ratings amid stable revenue around $17.8 billion.
PHG presents a recovery story with margin expansion and AI innovation driving upside potential, though execution risks and debt levels near 25% of assets warrant caution. The stock's 24.1 P/E appears reasonable if earnings growth sustains, but investors should monitor competitive pressures in healthcare technology and macroeconomic impacts on capital spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
